At the news
? BULLISHIMPACT 8/10 6-K filed Mar 27, 2026 at 08:04 ET
AstraZeneca announced positive high-level results from two Phase III trials (OBERON and TITANIA) showing that tozorakimab, an IL-33-targeting biologic, significantly reduced moderate-to-severe COPD exacerbations in a broad patient population. This marks the first time an IL-33 inhibitor has demonstrated such efficacy in replicate Phase III trials, representing a major scientific advancement in COPD treatment.
- Tozorakimab met primary endpoints in both OBERON and TITANIA Phase III trials, reducing annualized rates of moderate-to-severe COPD exacerbations versus placebo.
- The drug showed efficacy in former smokers (primary population), current smokers, across all blood eosinophil counts, and all stages of lung function severity.
- Tozorakimab was generally well tolerated with a favorable safety profile.
- It is a first-in-class monoclonal antibody targeting both reduced and oxidized forms of IL-33, uniquely inhibiting inflammation and mucus dysfunction in COPD.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access